GlassScriptPhysician profile
David A Konanc
NPI 1801842794
$13,011.01
in general payments reported to CMS, 2019-2025
82 companies · $2,662 in 2025
The $2,662 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,211 · 2020: $316 · 2021: $260 · 2022: $2,238 · 2023: $2,331 · 2024: $2,993 · 2025: $2,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,787 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,786.50 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,085.54 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $895.03 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $872.16 | 2019-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $602.67 | 2019-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $542.32 | 2023-2025 | Gocovri, Gocovri |
| Ucb, INC. | $477.63 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Biogen, INC. | $442.25 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Genzyme Corporation | $429.13 | 2019-2025 | |
| Genentech USA, INC. | $420.67 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $416.54 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Tg Therapeutics, INC. | $385.85 | 2024-2025 | |
| Amgen INC. | $368.97 | 2019-2025 | Uplizna |
| Argenx US, INC. | $367.86 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $299.32 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $289.44 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 80 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Konanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.